PolyPid
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
18 Hasivim St, Petah Tiqwa, Central Dist...Phone Number
+972 747195700Website
www.polypid.comRevenue
$25.8 MillionStock Symbol
PYPDIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.Explore more
PolyPid Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PolyPid your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if PolyPid is spiking on competitors!
Earning: See what the market has to say on PolyPid recently announced quarterly report
Product Launch: Get notified when PolyPid launches new products
Website visits: Recent activity has been detected on your website
PolyPid, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if PolyPid has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at PolyPid
Click to see if PolyPid had a recent Job posting/layoffs
Funding: Get notified immidiatlly once PolyPid has new funding data
Recommended Actions
Find VP level buyers at PolyPid
Find 2 more new buyers
Company Profile Activity
Activity Insights
PolyPid is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PolyPid is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PolyPid.
PolyPid financials insights
Gather financial insights about PolyPid, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$2.2M
2014
Series B
$10.9M
2015
Series C
$8.3M
2016
Series D
$22M
Private Equity
$5.3M
2019
Series E
$50M
2024
Debt
$14.5M
2025
Stock/Share Issuance
$26.7M
PolyPid Tech Stack
A closer look at the technologies used by PolyPid
See more technologies
Most Recent Scoops
Earnings
Event
Earnings, Events, Finance
Person-Based
Partnership
Person-Based
Partnership
Person-Based
Partnership, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
PolyPid News & Media
PolyPid Q2 Earnings Call Highlights
PolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA’s acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada. D-PLEX100 is being developed to prevent surgical site infections in pPolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated GuidancePolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 APolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PolyPid
Sign Up For FreeTo access detailed company insights
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal rel... Read More
